Longeveron
$0.6158
80
+$0.00+0.38% 16:50 Today
Statistics
Day High
0.6225
Day Low
0.5949
52W High
1.8
52W Low
0.475
Volume
1,508,262
Avg. Volume
-
Mkt Cap
19.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.43
-0.35
-0.26
-0.18
Expected EPS
-0.175
Actual EPS
N/A
Financials
-1,893.58%Profit Margin
Unprofitable1.2MRevenue
-22.7MNet Income
Analyst Ratings
8.00Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 50%
Hold 50%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow LGVN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2B
Biolife Solutions
BLFS
Mkt Cap1.38B
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
Editas Medicine
EDIT
Mkt Cap500.29M
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Vericel
VCEL
Mkt Cap2.4B
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Fate Therapeutics
FATE
Mkt Cap361.33M
About
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Show more...
CEO
Dr. Joshua Michael Hare FACC, M.D.
Employees
38
Country
United States
ISIN
US54303L2034
Listings
0 Comments
Share your thoughts
FAQ
What is Longeveron stock price today?▼
The current price of LGVN is $0.62 USD — it has increased by +0.38% in the past 24 hours. Watch Longeveron stock price performance more closely on the chart.
What is Longeveron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Longeveron stocks are traded under the ticker LGVN.
Is Longeveron stock price growing?▼
LGVN stock has fallen by -8.78% compared to the previous week, the month change is a -26.7% fall, over the last year Longeveron has showed a -60.02% decrease.
What is Longeveron market cap?▼
Today Longeveron has the market capitalization of 19.46M
When is the next Longeveron earnings date?▼
Longeveron is going to release the next earnings report on August 07, 2026.
What were Longeveron earnings last quarter?▼
LGVN earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.18 USD resulting in a -7.04% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Longeveron revenue for the last year?▼
Longeveron revenue for the last year amounts to 1.2M USD.
What is Longeveron net income for the last year?▼
LGVN net income for the last year is -22.7M USD.
How many employees does Longeveron have?▼
As of July 17, 2026, the company has 38 employees.
In which sector is Longeveron located?▼
Longeveron operates in the Health & Wellness sector.
When did Longeveron complete a stock split?▼
The last stock split for Longeveron was on March 27, 2024 with a ratio of 1:10.
Where is Longeveron headquartered?▼
Longeveron is headquartered in Miami, United States.